Dr Reddy’s Lab launches generic eye treatment medication in US
PTI, Jan 27, 2023, 5:13 PM IST
Representative Image (Source: Pexels)
New Delhi: Dr Reddy’s Laboratories on Friday said it has launched Difluprednate Ophthalmic Emulsion, used in the treatment of pain and swelling in the eyes caused by infection or allergy after eye surgery, in the American market.
The company has launched the medication, a generic version of Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, after getting approval from the US Food and Drug Administration (USFDA), the Hyderabad-based drug major said in a statement.
As per IQVIA data, the Durezol brand and generics had sales of around USD 40 million in the US for the most recent twelve months ending in November 2022. Dr Reddy’s shares on Friday ended 2.78 percent up at Rs 4,321.35 apiece on the BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Indian markets rebound sharply on buying in bank stocks, firm global trends
Markets rebound in early trade amid global rally, buying in ICICI Bank and Reliance
Elon Musk in Beijing amid efforts to promote Tesla’s autonomous driving tech
Corporate earnings, US Fed interest rate decision to drive markets in holiday-shortened week: Analysts
Pune court asks police to probe bribery allegations against IT major Cognizant
MUST WATCH
Latest Additions
ICG apprehends Indian fishing boat with 173 kg of narcotics; two crew members detained
Ahead of phase 3 polls, Congress and BJP spar in MP over quotas, Muslim appeasement
Ramanagara: Five students swept away by currents in Cauvery river
Prajwal Revanna suspended from JD(S), says Kumaraswamy
JD(S) MLA demands expulsion of Revanna, son; says charges against them embarrassing